Patents Assigned to Edison Pharmaceuticals, Inc.
-
Patent number: 9567279Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-to-cotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.Type: GrantFiled: September 10, 2015Date of Patent: February 14, 2017Assignee: Edison Pharmaceuticals, Inc.Inventor: Paul Mollard
-
Patent number: 9546132Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: August 18, 2015Date of Patent: January 17, 2017Assignee: Edison Pharmaceuticals, Inc.Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
-
Patent number: 9486435Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: December 30, 2014Date of Patent: November 8, 2016Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson
-
Patent number: 9464016Abstract: Methods of treating or suppressing oxidative stress disorders affecting normal electron flow in the cells, including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases, diseases of aging and diseases caused by reactive oxygen species are disclosed, as well as compounds useful in the methods of the invention, such as such as catechol or ortho-quinone derivatives of Formula (I).Type: GrantFiled: June 14, 2012Date of Patent: October 11, 2016Assignee: EDISON PHARMACEUTICALS, INC.Inventors: Paul Mollard, Gloria Pfister
-
Patent number: 9447006Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: June 1, 2006Date of Patent: September 20, 2016Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Sidney M. Hecht
-
Patent number: 9399612Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.Type: GrantFiled: January 26, 2015Date of Patent: July 26, 2016Assignee: Edison Pharmaceuticals, Inc.Inventor: Guy M. Miller
-
Patent number: 9370496Abstract: The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.Type: GrantFiled: April 9, 2013Date of Patent: June 21, 2016Assignee: EDISON PHARMACEUTICALS, INC.Inventor: Guy M. Miller
-
Patent number: 9296712Abstract: Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.Type: GrantFiled: March 15, 2013Date of Patent: March 29, 2016Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Dana Davis, William D. Shrader
-
Patent number: 9278085Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: February 22, 2007Date of Patent: March 8, 2016Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Sidney M. Hecht, Orion D. Jankowski, Kieron E. Wesson, Paul Mollard
-
Patent number: 9169196Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: June 21, 2013Date of Patent: October 27, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Orion D. Jankowski, Kieron E. Wesson, Paul Mollard, William D. Shrader
-
Patent number: 9162957Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-tocotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.Type: GrantFiled: July 19, 2012Date of Patent: October 20, 2015Assignee: Edison Pharmaceuticals, Inc.Inventor: Paul Mollard
-
Publication number: 20150218079Abstract: Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: R1 and R2 are independently hydrogen, (C1-C6)alkyl or —O(C1-C6)alkyl; or R1 and R2 together represent —CH?CH—CH?CH—; R3 is (C1-C6)alkyl; X is —CH?CH— or —C?C—; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the —X—(CH2)n— group; Y is —OR4, —CN, —C(=0)OR5, —C(=0)R5, or —C(=0)N(R6)2; R4 and R5 are independently selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(=0)-(C1-C6)alkyl, —C(=0)-(C1-C6)haloalkyl, —C(=0)-NH(C1-C6)alkyl, —C(=0)-N((C1-C6)alkyl)2,Type: ApplicationFiled: September 6, 2013Publication date: August 6, 2015Applicant: Edison Pharmaceuticals, Inc.Inventors: William D. Shrader, Andrew W. Hinman, Viktoria Kheifets
-
Patent number: 9090576Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.Type: GrantFiled: March 24, 2014Date of Patent: July 28, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, William D. Shrader, Edgar P. Lee
-
Patent number: 9073873Abstract: Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives.Type: GrantFiled: March 24, 2014Date of Patent: July 7, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Orion D. Jankowski, Kieron E. Wesson
-
Patent number: 8969420Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD—not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.Type: GrantFiled: January 14, 2014Date of Patent: March 3, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Guy M. Miller, Viktoria Kheifets
-
Patent number: 8952071Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.Type: GrantFiled: January 6, 2009Date of Patent: February 10, 2015Assignee: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson
-
Publication number: 20140329860Abstract: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-substituted-p-quinone derivatives as disclosed herein.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Applicant: Edison Pharmaceuticals, Inc.Inventors: Andrew W. Hinman, Kieron E. Wesson, Orion D. Jankowski, Paul Mollard, William D. Shrader, Christopher R. Cornell
-
Publication number: 20140323509Abstract: Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives.Type: ApplicationFiled: March 24, 2014Publication date: October 30, 2014Applicant: Edison Pharmaceuticals, Inc.Inventors: Andrew W. HINMAN, Orion D. JANKOWSKI, Kieron E. WESSON
-
Publication number: 20140275045Abstract: Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: EDISON PHARMACEUTICALS, INC.Inventors: Andrew W. HINMAN, Dana Davis, William D. Shrader
-
Publication number: 20140275054Abstract: Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Edison Pharmaceuticals, Inc.Inventors: Andrew W. HINMAN, Dana Davis, William D. Shrader